The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma ...

Investigators sought to determine whether adjuvant pembrolizumab is associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma.

The LITESPARK-022 study tested belzutifan, an oral small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α) targeting angiogenesis, in combination with standard of care pembrolizumab as ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved cemiplimab-rwlc for adjuvant treatment of adults with cutaneous squamous cell carcinoma at ...

Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus ...